1. Home
  2. LEE vs SCYX Comparison

LEE vs SCYX Comparison

Compare LEE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

HOLD

Current Price

$5.24

Market Cap

31.3M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.67

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEE
SCYX
Founded
1890
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.3M
26.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
LEE
SCYX
Price
$5.24
$0.67
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
88.4K
371.4K
Earning Date
02-05-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$562,341,000.00
$2,932,000.00
Revenue This Year
$5.48
$170.77
Revenue Next Year
N/A
$286.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$0.57
52 Week High
$15.15
$1.31

Technical Indicators

Market Signals
Indicator
LEE
SCYX
Relative Strength Index (RSI) 66.83 55.71
Support Level $4.60 $0.63
Resistance Level $5.33 $0.68
Average True Range (ATR) 0.43 0.03
MACD 0.07 0.00
Stochastic Oscillator 78.74 60.52

Price Performance

Historical Comparison
LEE
SCYX

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: